{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:54:47Z","timestamp":1791863687259,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ardea Biosciences"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.tox.2018.05.002","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T11:55:07Z","timestamp":1525521307000},"page":"10-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Transporter-dependent cytotoxicity of antiviral drugs in primary cultures of human proximal tubular cells"],"prefix":"10.1016","volume":"404-405","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3239-4481","authenticated-orcid":false,"given":"Lawrence H.","family":"Lash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clynn","family":"Wilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2018.05.002_bib0005","article-title":"Tenofovir: is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?","volume":"18","author":"Aloy","year":"2016","journal-title":"AIDS Rev."},{"key":"10.1016\/j.tox.2018.05.002_bib0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1399-3046.2008.00937.x","article-title":"Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy","volume":"12","author":"Araya","year":"2008","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.tox.2018.05.002_bib0015","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.tox.2018.05.002_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.01183-08","article-title":"Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation","volume":"53","author":"Cihlar","year":"2009","journal-title":"Antimicr. Agents Chemother."},{"key":"10.1016\/j.tox.2018.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1517\/14656560902960154","article-title":"Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions","volume":"10","author":"Coremans","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.tox.2018.05.002_bib0030","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/toxsci\/53.2.458","article-title":"Metabolism and toxicity of trichloroethylene and S-(1,2-dichlorovinyl)-L-cysteine in freshly isolated human proximal tubular cells","volume":"53","author":"Cummings","year":"2000","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2018.05.002_bib0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0022-3565(24)39284-5","article-title":"Expression of glutathione-dependent enzymes and cytochrome P450\u202fs in freshly isolated and primary cultures of proximal tubular cells from human kidney","volume":"293","author":"Cummings","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2018.05.002_bib0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0090-9556(25)07423-9","article-title":"Pharmacokinetics of cidofovir in monkeys: evidence for a prolonged elimination phase representing phosphorylated drug","volume":"24","author":"Cundy","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2146\/ajhp120030","article-title":"Tenofovir-related nephrotoxicity: an ongoing clinical challenge","volume":"70","author":"Foisy","year":"2013","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.tox.2018.05.002_bib0050","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/acs.jmedchem.5b01593","article-title":"Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B","volume":"59","author":"Gallardo-Godoy","year":"2016","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.tox.2018.05.002_bib0055","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1060028016660812","article-title":"Tenofovir alafenamide: a review of its use in the treatment of HIV-1 infection","volume":"50","author":"Gibson","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tox.2018.05.002_bib0060","first-page":"148","article-title":"Letter to the editor: tenofovir-Induced nephrotoxicity: myths and facts","volume":"23","author":"Gupta","year":"2012","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.tox.2018.05.002_bib0065","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00467-012-2269-7","article-title":"Update on tenofovir toxicity in the kidney","volume":"28","author":"Hall","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.tox.2018.05.002_bib0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","article-title":"Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1","volume":"11","author":"Ho","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.tox.2018.05.002_bib0075","doi-asserted-by":"crossref","first-page":"e00148","DOI":"10.1002\/prp2.148","article-title":"Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells","volume":"3","author":"Huang","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tox.2018.05.002_bib0080","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00228-014-1712-z","article-title":"Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention","volume":"70","author":"Jafari","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2018.05.002_bib0085","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.qai.0000243103.03265.2b","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"Kearny","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tox.2018.05.002_bib0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/44.2.97","article-title":"Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys","volume":"44","author":"Lacy","year":"1998","journal-title":"Toxic Sci."},{"key":"10.1016\/j.tox.2018.05.002_bib0095","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.tox.2018.05.002_bib0100","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00042560-199700001-00005","article-title":"Cidofovir: a new therapy for cytomegalovirus retinitis","volume":"14","author":"Lalezari","year":"1997","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"10.1016\/j.tox.2018.05.002_bib0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0300-483X(95)03110-2","article-title":"Susceptibility of primary cultures of proximal tubular and distal tubular cells from rat kidney to chemically induced toxicity","volume":"103","author":"Lash","year":"1995","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2018.05.002_bib0110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tox.2006.08.035","article-title":"Membrane transport function in primary cultures of human proximal tubular cells","volume":"228","author":"Lash","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.tox.2018.05.002_bib0115","article-title":"Human proximal tubular cells as an in vitro model for drug screening and mechanistic toxicology","author":"Lash","year":"2012","journal-title":"AltTox Essay"},{"key":"10.1016\/j.tox.2018.05.002_bib0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","volume":"52","author":"Lea","year":"1996","journal-title":"Cidofovir. Drugs"},{"key":"10.1016\/j.tox.2018.05.002_bib0125","first-page":"580","article-title":"Renal tubular dysfunction associated with tenofovir therapy","volume":"62","author":"Mitra","year":"2014","journal-title":"J. Assoc. Phys. India"},{"key":"10.1016\/j.tox.2018.05.002_bib0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/0897190012442718","article-title":"Renal toxicity of long-term therapy with tenofovir in HIV-infected patients","volume":"25","author":"Monteagudo-Cho","year":"2012","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.tox.2018.05.002_bib0135","first-page":"1","article-title":"Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen","volume":"22","author":"Mouton","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2018.05.002_bib0140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.117.243139","article-title":"Factors contributing to the antiretroviral effectiveness of tenofovir","volume":"363","author":"Murphy","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2018.05.002_bib0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ajhp\/54.1.12","article-title":"Gilead issues new warnings about cidofovir nephrotoxicity","volume":"54","author":"News","year":"1997","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.tox.2018.05.002_bib0150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1208\/s12248-016-9871-8","article-title":"A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity","volume":"18","author":"Nieskens","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.tox.2018.05.002_bib0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0926-6569(63)90197-4","article-title":"\u03b3-Glutamyl-p-nitroanilide: a new convenient substrate for determination and study of L- and D-\u03b3-glutamyltranspeptidase activities","volume":"73","author":"Orlowski","year":"1963","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tox.2018.05.002_bib0160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/135965350501000110","article-title":"Tubular cell apoptosis and cidofovir-induced acute renal failure","volume":"10","author":"Ortiz","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tox.2018.05.002_bib0165","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tox.2018.05.002_bib0170","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/B978-0-12-800223-0.00006-2","article-title":"SLC22, SLC44, and SLC47 transporters- organic anion and cation transporters: molecular and cellular properties","volume":"73","author":"Pelis","year":"2014","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.tox.2018.05.002_bib0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.116.238337","article-title":"Letter to the Editor: tenofovir disoproxil fumarate is not an inhibitor of human organic cation transporter 1","volume":"360","author":"Shen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2018.05.002_bib0180","series-title":"Methods Molecular Medicine","article-title":"Chapter 32. Enzymatic isolation and serum-free culture of human renal cells","author":"Todd","year":"1996"},{"key":"10.1016\/j.tox.2018.05.002_bib0185","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?","volume":"24","author":"Tourret","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tox.2018.05.002_bib0190","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/toxsci\/kfw208","article-title":"Comparative renal safety assessment of the hepatitis B drugs adefovir, tenofovir, telbivudine and entecavir in rats","volume":"155","author":"Uteng","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2018.05.002_bib0195","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11095-006-9196-x","article-title":"Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)","volume":"24","author":"Uwai","year":"2007","journal-title":"Pharmaceut Res"},{"key":"10.1016\/j.tox.2018.05.002_bib0200","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.kint.2015.11.014","article-title":"Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?","volume":"89","author":"Wyatt","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.tox.2018.05.002_bib0205","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/pgs.11.137","article-title":"Pharmacogenetics of drugs withdrawn from the market","volume":"13","author":"Zhang","year":"2012","journal-title":"Pharmacogenomics"}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X18300672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X18300672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:38:10Z","timestamp":1759534690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X18300672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":41,"alternative-id":["S0300483X18300672"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2018.05.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733401566.793555239","asserted-by":"object"}]},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transporter-dependent cytotoxicity of antiviral drugs in primary cultures of human proximal tubular cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2018.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}